Nelarabine monotherapy for r/r T-ALL/T-LBL (adult dosing)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-NELARABINE |
|---|
| ID | REG-NELARABINE-TCELL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
Adult dosing per Gökbuget 2017 schema; pediatric dosing (650 mg/m² daily × 5) used in BFM-style protocols. Bridge to alloSCT preferred in fit responders — sustained CR uncommon without consolidation. Stop drug at first sign of Grade ≥2 neurologic toxicity — irreversible Guillain-Barré-like syndromes reported.
Used By
Indication
IND-T-ALL-2L-NELARABINE- IND-T-ALL-2L-NELARABINE